Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Decreases By 15.9%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) saw a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 618,000 shares, a decline of 15.9% from the April 15th total of 734,900 shares. Based on an average trading volume of 403,300 shares, the short-interest ratio is currently 1.5 days. Approximately 2.9% of the company’s shares are short sold.

A number of hedge funds have recently added to or reduced their stakes in XFOR. Connor Clark & Lunn Investment Management Ltd. bought a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $29,000. Virtu Financial LLC bought a new position in shares of X4 Pharmaceuticals during the 1st quarter valued at $45,000. Goldman Sachs Group Inc. lifted its holdings in shares of X4 Pharmaceuticals by 100.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 20,949 shares of the company’s stock valued at $48,000 after buying an additional 10,474 shares during the period. Norges Bank bought a new position in X4 Pharmaceuticals in the 4th quarter worth $63,000. Finally, Jane Street Group LLC bought a new position in X4 Pharmaceuticals in the 1st quarter worth $64,000. 76.63% of the stock is currently owned by institutional investors and hedge funds.

XFOR stock opened at $1.15 on Wednesday. X4 Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $9.90. The business’s 50 day moving average price is $1.56 and its two-hundred day moving average price is $2.38. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.73 and a current ratio of 4.73. The company has a market capitalization of $35.45 million, a price-to-earnings ratio of -0.33 and a beta of 0.62.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.10). During the same period in the prior year, the firm posted ($1.30) earnings per share. Sell-side analysts forecast that X4 Pharmaceuticals will post -2.53 earnings per share for the current year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered X4 Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 17th. Canaccord Genuity Group lowered their target price on X4 Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, April 5th. HC Wainwright lowered their target price on X4 Pharmaceuticals from $11.00 to $8.50 in a research note on Friday, May 13th. Canaccord Genuity Group reduced their price target on X4 Pharmaceuticals from $20.00 to $10.00 in a report on Tuesday, April 5th. Finally, Stifel Nicolaus reduced their price target on X4 Pharmaceuticals from $19.00 to $10.00 in a report on Thursday, March 17th.

X4 Pharmaceuticals Company Profile (Get Rating)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Read More